Cargando…
Safety and Immunogenicity of an Inactivated COVID-19 Vaccine, WIBP-CorV, in Healthy Children: Interim Analysis of a Randomized, Double-Blind, Controlled, Phase 1/2 Trial
Safe and effective vaccines against SARS-CoV-2 for children are urgently needed. Here we aimed to assess the safety and immunogenicity of an inactivated COVID-19 vaccine candidate, WIBP-CorV, in participants aged 3-17 years. A randomized, double-blind, placebo-controlled, phase 1/2 clinical trial wa...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9265248/ https://www.ncbi.nlm.nih.gov/pubmed/35812412 http://dx.doi.org/10.3389/fimmu.2022.898151 |
_version_ | 1784743166693343232 |
---|---|
author | Xia, Shengli Duan, Kai Zhang, Yuntao Zeng, Xiaoqing Zhao, Dongyang Zhang, Huajun Xie, Zhiqiang Li, Xinguo Peng, Cheng Zhang, Wei Yang, Yunkai Chen, Wei Gao, Xiaoxiao You, Wangyang Wang, Xuewei Wang, Zejun Shi, Zhengli Wang, Yanxia Yang, Xuqin Li, Qingliang Huang, Lili Wang, Qian Lu, Jia Yang, Yongli Guo, Jing Zhou, Wei Wan, Xin Wu, Cong Wang, Wenhui Huang, Shihe Du, Jianhui Nian, Xuanxuan Deng, Tao Yuan, Zhiming Shen, Shuo Guo, Wanshen Liu, Jia Yang, Xiaoming |
author_facet | Xia, Shengli Duan, Kai Zhang, Yuntao Zeng, Xiaoqing Zhao, Dongyang Zhang, Huajun Xie, Zhiqiang Li, Xinguo Peng, Cheng Zhang, Wei Yang, Yunkai Chen, Wei Gao, Xiaoxiao You, Wangyang Wang, Xuewei Wang, Zejun Shi, Zhengli Wang, Yanxia Yang, Xuqin Li, Qingliang Huang, Lili Wang, Qian Lu, Jia Yang, Yongli Guo, Jing Zhou, Wei Wan, Xin Wu, Cong Wang, Wenhui Huang, Shihe Du, Jianhui Nian, Xuanxuan Deng, Tao Yuan, Zhiming Shen, Shuo Guo, Wanshen Liu, Jia Yang, Xiaoming |
author_sort | Xia, Shengli |
collection | PubMed |
description | Safe and effective vaccines against SARS-CoV-2 for children are urgently needed. Here we aimed to assess the safety and immunogenicity of an inactivated COVID-19 vaccine candidate, WIBP-CorV, in participants aged 3-17 years. A randomized, double-blind, placebo-controlled, phase 1/2 clinical trial was conducted in Henan Province, China, in healthy children aged 3-17 years. 240 participants in phase 1 trial and 576 participants in phase 2 trial were randomly assigned to vaccine or control with an age de-escalation in three cohorts (3-5, 6-12 and 13-17 years) and dose-escalation in three groups (2.5, 5.0 and 10.0μg/dose), and received 3 intramuscular injections at day 0, 28, and 56. WIBP-CorV showed a promising safety profile with approximately 17% adverse reactions within 30 days after injection and no grade 3 or worse adverse events. The most common adverse reaction was injection site pain, followed by fever, which were mild and self-limiting. The geometric mean titers of neutralizing antibody ranged from 102.2 to 1065.5 in vaccinated participants at 28 days after the third vaccination, and maintained at a range of 14.3 to 218.2 at day 180 after the third vaccination. WIBP-CorV elicited significantly higher titers of neutralizing antibody in the cohort aged 3-5 years than the other two cohorts. There were no detectable antibody responses in all alum-only groups. Taken together, our data demonstrate that WIBP-CorV is safe and well tolerated at all tested doses in participants aged 3-17 years, and elicited robust humoral responses against SARS-CoV-2 lasted for at least 6 months after the third vaccination. This study is ongoing and is registered with www.chictr.org.cn, ChiCTR2000031809. |
format | Online Article Text |
id | pubmed-9265248 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92652482022-07-09 Safety and Immunogenicity of an Inactivated COVID-19 Vaccine, WIBP-CorV, in Healthy Children: Interim Analysis of a Randomized, Double-Blind, Controlled, Phase 1/2 Trial Xia, Shengli Duan, Kai Zhang, Yuntao Zeng, Xiaoqing Zhao, Dongyang Zhang, Huajun Xie, Zhiqiang Li, Xinguo Peng, Cheng Zhang, Wei Yang, Yunkai Chen, Wei Gao, Xiaoxiao You, Wangyang Wang, Xuewei Wang, Zejun Shi, Zhengli Wang, Yanxia Yang, Xuqin Li, Qingliang Huang, Lili Wang, Qian Lu, Jia Yang, Yongli Guo, Jing Zhou, Wei Wan, Xin Wu, Cong Wang, Wenhui Huang, Shihe Du, Jianhui Nian, Xuanxuan Deng, Tao Yuan, Zhiming Shen, Shuo Guo, Wanshen Liu, Jia Yang, Xiaoming Front Immunol Immunology Safe and effective vaccines against SARS-CoV-2 for children are urgently needed. Here we aimed to assess the safety and immunogenicity of an inactivated COVID-19 vaccine candidate, WIBP-CorV, in participants aged 3-17 years. A randomized, double-blind, placebo-controlled, phase 1/2 clinical trial was conducted in Henan Province, China, in healthy children aged 3-17 years. 240 participants in phase 1 trial and 576 participants in phase 2 trial were randomly assigned to vaccine or control with an age de-escalation in three cohorts (3-5, 6-12 and 13-17 years) and dose-escalation in three groups (2.5, 5.0 and 10.0μg/dose), and received 3 intramuscular injections at day 0, 28, and 56. WIBP-CorV showed a promising safety profile with approximately 17% adverse reactions within 30 days after injection and no grade 3 or worse adverse events. The most common adverse reaction was injection site pain, followed by fever, which were mild and self-limiting. The geometric mean titers of neutralizing antibody ranged from 102.2 to 1065.5 in vaccinated participants at 28 days after the third vaccination, and maintained at a range of 14.3 to 218.2 at day 180 after the third vaccination. WIBP-CorV elicited significantly higher titers of neutralizing antibody in the cohort aged 3-5 years than the other two cohorts. There were no detectable antibody responses in all alum-only groups. Taken together, our data demonstrate that WIBP-CorV is safe and well tolerated at all tested doses in participants aged 3-17 years, and elicited robust humoral responses against SARS-CoV-2 lasted for at least 6 months after the third vaccination. This study is ongoing and is registered with www.chictr.org.cn, ChiCTR2000031809. Frontiers Media S.A. 2022-06-24 /pmc/articles/PMC9265248/ /pubmed/35812412 http://dx.doi.org/10.3389/fimmu.2022.898151 Text en Copyright © 2022 Xia, Duan, Zhang, Zeng, Zhao, Zhang, Xie, Li, Peng, Zhang, Yang, Chen, Gao, You, Wang, Wang, Shi, Wang, Yang, Li, Huang, Wang, Lu, Yang, Guo, Zhou, Wan, Wu, Wang, Huang, Du, Nian, Deng, Yuan, Shen, Guo, Liu and Yang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Xia, Shengli Duan, Kai Zhang, Yuntao Zeng, Xiaoqing Zhao, Dongyang Zhang, Huajun Xie, Zhiqiang Li, Xinguo Peng, Cheng Zhang, Wei Yang, Yunkai Chen, Wei Gao, Xiaoxiao You, Wangyang Wang, Xuewei Wang, Zejun Shi, Zhengli Wang, Yanxia Yang, Xuqin Li, Qingliang Huang, Lili Wang, Qian Lu, Jia Yang, Yongli Guo, Jing Zhou, Wei Wan, Xin Wu, Cong Wang, Wenhui Huang, Shihe Du, Jianhui Nian, Xuanxuan Deng, Tao Yuan, Zhiming Shen, Shuo Guo, Wanshen Liu, Jia Yang, Xiaoming Safety and Immunogenicity of an Inactivated COVID-19 Vaccine, WIBP-CorV, in Healthy Children: Interim Analysis of a Randomized, Double-Blind, Controlled, Phase 1/2 Trial |
title | Safety and Immunogenicity of an Inactivated COVID-19 Vaccine, WIBP-CorV, in Healthy Children: Interim Analysis of a Randomized, Double-Blind, Controlled, Phase 1/2 Trial |
title_full | Safety and Immunogenicity of an Inactivated COVID-19 Vaccine, WIBP-CorV, in Healthy Children: Interim Analysis of a Randomized, Double-Blind, Controlled, Phase 1/2 Trial |
title_fullStr | Safety and Immunogenicity of an Inactivated COVID-19 Vaccine, WIBP-CorV, in Healthy Children: Interim Analysis of a Randomized, Double-Blind, Controlled, Phase 1/2 Trial |
title_full_unstemmed | Safety and Immunogenicity of an Inactivated COVID-19 Vaccine, WIBP-CorV, in Healthy Children: Interim Analysis of a Randomized, Double-Blind, Controlled, Phase 1/2 Trial |
title_short | Safety and Immunogenicity of an Inactivated COVID-19 Vaccine, WIBP-CorV, in Healthy Children: Interim Analysis of a Randomized, Double-Blind, Controlled, Phase 1/2 Trial |
title_sort | safety and immunogenicity of an inactivated covid-19 vaccine, wibp-corv, in healthy children: interim analysis of a randomized, double-blind, controlled, phase 1/2 trial |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9265248/ https://www.ncbi.nlm.nih.gov/pubmed/35812412 http://dx.doi.org/10.3389/fimmu.2022.898151 |
work_keys_str_mv | AT xiashengli safetyandimmunogenicityofaninactivatedcovid19vaccinewibpcorvinhealthychildreninterimanalysisofarandomizeddoubleblindcontrolledphase12trial AT duankai safetyandimmunogenicityofaninactivatedcovid19vaccinewibpcorvinhealthychildreninterimanalysisofarandomizeddoubleblindcontrolledphase12trial AT zhangyuntao safetyandimmunogenicityofaninactivatedcovid19vaccinewibpcorvinhealthychildreninterimanalysisofarandomizeddoubleblindcontrolledphase12trial AT zengxiaoqing safetyandimmunogenicityofaninactivatedcovid19vaccinewibpcorvinhealthychildreninterimanalysisofarandomizeddoubleblindcontrolledphase12trial AT zhaodongyang safetyandimmunogenicityofaninactivatedcovid19vaccinewibpcorvinhealthychildreninterimanalysisofarandomizeddoubleblindcontrolledphase12trial AT zhanghuajun safetyandimmunogenicityofaninactivatedcovid19vaccinewibpcorvinhealthychildreninterimanalysisofarandomizeddoubleblindcontrolledphase12trial AT xiezhiqiang safetyandimmunogenicityofaninactivatedcovid19vaccinewibpcorvinhealthychildreninterimanalysisofarandomizeddoubleblindcontrolledphase12trial AT lixinguo safetyandimmunogenicityofaninactivatedcovid19vaccinewibpcorvinhealthychildreninterimanalysisofarandomizeddoubleblindcontrolledphase12trial AT pengcheng safetyandimmunogenicityofaninactivatedcovid19vaccinewibpcorvinhealthychildreninterimanalysisofarandomizeddoubleblindcontrolledphase12trial AT zhangwei safetyandimmunogenicityofaninactivatedcovid19vaccinewibpcorvinhealthychildreninterimanalysisofarandomizeddoubleblindcontrolledphase12trial AT yangyunkai safetyandimmunogenicityofaninactivatedcovid19vaccinewibpcorvinhealthychildreninterimanalysisofarandomizeddoubleblindcontrolledphase12trial AT chenwei safetyandimmunogenicityofaninactivatedcovid19vaccinewibpcorvinhealthychildreninterimanalysisofarandomizeddoubleblindcontrolledphase12trial AT gaoxiaoxiao safetyandimmunogenicityofaninactivatedcovid19vaccinewibpcorvinhealthychildreninterimanalysisofarandomizeddoubleblindcontrolledphase12trial AT youwangyang safetyandimmunogenicityofaninactivatedcovid19vaccinewibpcorvinhealthychildreninterimanalysisofarandomizeddoubleblindcontrolledphase12trial AT wangxuewei safetyandimmunogenicityofaninactivatedcovid19vaccinewibpcorvinhealthychildreninterimanalysisofarandomizeddoubleblindcontrolledphase12trial AT wangzejun safetyandimmunogenicityofaninactivatedcovid19vaccinewibpcorvinhealthychildreninterimanalysisofarandomizeddoubleblindcontrolledphase12trial AT shizhengli safetyandimmunogenicityofaninactivatedcovid19vaccinewibpcorvinhealthychildreninterimanalysisofarandomizeddoubleblindcontrolledphase12trial AT wangyanxia safetyandimmunogenicityofaninactivatedcovid19vaccinewibpcorvinhealthychildreninterimanalysisofarandomizeddoubleblindcontrolledphase12trial AT yangxuqin safetyandimmunogenicityofaninactivatedcovid19vaccinewibpcorvinhealthychildreninterimanalysisofarandomizeddoubleblindcontrolledphase12trial AT liqingliang safetyandimmunogenicityofaninactivatedcovid19vaccinewibpcorvinhealthychildreninterimanalysisofarandomizeddoubleblindcontrolledphase12trial AT huanglili safetyandimmunogenicityofaninactivatedcovid19vaccinewibpcorvinhealthychildreninterimanalysisofarandomizeddoubleblindcontrolledphase12trial AT wangqian safetyandimmunogenicityofaninactivatedcovid19vaccinewibpcorvinhealthychildreninterimanalysisofarandomizeddoubleblindcontrolledphase12trial AT lujia safetyandimmunogenicityofaninactivatedcovid19vaccinewibpcorvinhealthychildreninterimanalysisofarandomizeddoubleblindcontrolledphase12trial AT yangyongli safetyandimmunogenicityofaninactivatedcovid19vaccinewibpcorvinhealthychildreninterimanalysisofarandomizeddoubleblindcontrolledphase12trial AT guojing safetyandimmunogenicityofaninactivatedcovid19vaccinewibpcorvinhealthychildreninterimanalysisofarandomizeddoubleblindcontrolledphase12trial AT zhouwei safetyandimmunogenicityofaninactivatedcovid19vaccinewibpcorvinhealthychildreninterimanalysisofarandomizeddoubleblindcontrolledphase12trial AT wanxin safetyandimmunogenicityofaninactivatedcovid19vaccinewibpcorvinhealthychildreninterimanalysisofarandomizeddoubleblindcontrolledphase12trial AT wucong safetyandimmunogenicityofaninactivatedcovid19vaccinewibpcorvinhealthychildreninterimanalysisofarandomizeddoubleblindcontrolledphase12trial AT wangwenhui safetyandimmunogenicityofaninactivatedcovid19vaccinewibpcorvinhealthychildreninterimanalysisofarandomizeddoubleblindcontrolledphase12trial AT huangshihe safetyandimmunogenicityofaninactivatedcovid19vaccinewibpcorvinhealthychildreninterimanalysisofarandomizeddoubleblindcontrolledphase12trial AT dujianhui safetyandimmunogenicityofaninactivatedcovid19vaccinewibpcorvinhealthychildreninterimanalysisofarandomizeddoubleblindcontrolledphase12trial AT nianxuanxuan safetyandimmunogenicityofaninactivatedcovid19vaccinewibpcorvinhealthychildreninterimanalysisofarandomizeddoubleblindcontrolledphase12trial AT dengtao safetyandimmunogenicityofaninactivatedcovid19vaccinewibpcorvinhealthychildreninterimanalysisofarandomizeddoubleblindcontrolledphase12trial AT yuanzhiming safetyandimmunogenicityofaninactivatedcovid19vaccinewibpcorvinhealthychildreninterimanalysisofarandomizeddoubleblindcontrolledphase12trial AT shenshuo safetyandimmunogenicityofaninactivatedcovid19vaccinewibpcorvinhealthychildreninterimanalysisofarandomizeddoubleblindcontrolledphase12trial AT guowanshen safetyandimmunogenicityofaninactivatedcovid19vaccinewibpcorvinhealthychildreninterimanalysisofarandomizeddoubleblindcontrolledphase12trial AT liujia safetyandimmunogenicityofaninactivatedcovid19vaccinewibpcorvinhealthychildreninterimanalysisofarandomizeddoubleblindcontrolledphase12trial AT yangxiaoming safetyandimmunogenicityofaninactivatedcovid19vaccinewibpcorvinhealthychildreninterimanalysisofarandomizeddoubleblindcontrolledphase12trial |